Immunic Inc

Price Chart

Risk-Adjusted Performance

Immunic Inc (IMUX) Price Performance

Immunic Inc (IMUX) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $1.25, up 13.64% from the previous close.

Over the past year, IMUX has traded between a low of $0.51 and a high of $1.45. The stock has gained 4.2% over this period. It is currently 13.8% below its 52-week high.

Immunic Inc has a market capitalization of $163.08M.

About Immunic Inc

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.